Core Viewpoint - A class action securities lawsuit has been filed against Caribou Biosciences, Inc. alleging securities fraud that affected investors between July 14, 2023, and July 16, 2024 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Caribou Biosciences overstated the safety, efficacy, and durability of its product CB-010 compared to approved CAR-T cell therapies for treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL) [2]. - It is alleged that Caribou faced significant risks regarding insufficient cash and liquidity to fund its business operations, including preclinical research for its allogeneic CAR-NK platform [2]. - The lawsuit suggests that these issues were likely to have a substantial negative impact on Caribou's business and operations, rendering the defendants' public statements materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until February 24, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].
Shareholders of Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU